VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

IMW 2019 | Myeloma: immunomodulatory therapy and CHIP

Tarek H Mouhieddine, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the rationale behind the use of immunomodulatory therapy in the treatment of multiple myeloma and the importance of clonal hematopoiesis of undetermined potential (CHIP) at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter